(Q37857919)

24 August 2017

1 reference

title

Clinical psychopharmacology of eating disorders: a research update (English)

1 reference

24 August 2017

1 reference

1

Phillipa J Hay

1 reference

24 August 2017

Angélica M Claudino

2

1 reference

24 August 2017

25 March 2011

1 reference

The International Journal of Neuropsychopharmacology

24 August 2017

1 reference

24 August 2017

15

1 reference

24 August 2017

2

1 reference

24 August 2017

209-222

1 reference

Predictors of treatment acceptance and completion in anorexia nervosa: implications for future study designs

24 August 2017

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized double-blind placebo-controlled comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Effect of orlistat in obese patients with binge eating disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Comorbidity studies of eating disorders and mood disorders. Critical review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Epigenetic dysregulation of dopaminergic genes in eating disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Drug treatment for bulimia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Psychiatric comorbidity in a Brazilian sample of patients with binge-eating disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating-specific psychopathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Use of reboxetine in bulimia nervosa: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Milnacipran in the treatment of bulimia nervosa: a report of 16 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

The role of olanzapine in the treatment of anorexia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Anorexia nervosa and major depression: shared genetic and environmental risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Cognitive behavioral therapy and fluoxetine as adjuncts to group behavioral therapy for binge eating disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Atypical antipsychotics and anorexia nervosa: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Investigating the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Placebo-controlled trial of sertraline in the treatment of binge eating disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Aripiprazole in anorexia nervosa and low-weight bulimia nervosa: case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Atypical antipsychotics and weight gain--a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Early response to antidepressant treatment in bulimia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Controlled family study of anorexia nervosa and bulimia nervosa: evidence of shared liability and transmission of partial syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

The impact of obesity on health care costs among persons with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

The application of exposure therapy and D-cycloserine to the treatment of anorexia nervosa: a preliminary trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Antidepressants in short-term treatment of binge eating disorder: systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Anorexia nervosa treatment: a systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Binge eating disorder treatment: a systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Baclofen for binge eating: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Memantine in the treatment of binge eating disorder: an open-label, prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Meta-analysis: pharmacologic treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Olanzapine therapy in anorexia nervosa: psychobiological effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Low-dose olanzapine monotherapy in girls with anorexia nervosa, restricting subtype: focus on hyperactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Association between serotonin transporter gene polymorphism and eating disorders: a meta-analytic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Bulimia nervosa treatment: a systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Reboxetine in the treatment of bulimia nervosa: a report of seven cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Australian and New Zealand clinical practice guidelines for the treatment of anorexia nervosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Fluoxetine and fluvoxamine combined with individual cognitive-behaviour therapy in binge eating disorder: a one-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Review and meta-analysis of pharmacotherapy for binge-eating disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Available pharmacological treatments for anorexia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Successful duloxetine treatment of a binge eating disorder: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Quetiapine in anorexia nervosa patients: an open label outpatient pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Predictors of Weight Loss in Adults with Topiramate‐Treated Epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Topiramate in the treatment of severe bulimia nervosa with comorbid mood disorders: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Serotonin alterations in anorexia and bulimia nervosa: new insights from imaging studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Use of nutritional supplements to increase the efficacy of fluoxetine in the treatment of anorexia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Serotonin transporter binding after recovery from eating disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Comorbidity of anxiety disorders with anorexia and bulimia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Placebo response in binge eating disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Effects of milnacipran on binge eating - a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Treatment of bulimia nervosa with fluvoxamine: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Review of the use of Topiramate for treatment of psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Treatment of bulimia nervosa with sertraline: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Pharmacological approaches in the treatment of binge eating disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

A Randomized, Double-blind, Placebo-Controlled Study of Sibutramine in the Treatment of Binge-Eating Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Pharmacologic and cognitive-behavioral treatment for bulimia nervosa: a controlled comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Longitudinal study of the diagnosis of components of the metabolic syndrome in individuals with binge-eating disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Does the thrifty phenotype result from chronic glutamate intoxication? A hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

Eating disorder behaviors are increasing: findings from two sequential community surveys in South Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

A double-blind controlled trial of lithium carbonate primary anorexia nervosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

7 January 2021

Long-term fluoxetine treatment of bulimia nervosa. Fluoxetine Bulimia Nervosa Research Group

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

7 January 2021

Anorexia nervosa. Treatment efficacy of cyproheptadine and amitriptyline

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

7 January 2021

Fluoxetine versus placebo: a double-blind study with bulimic inpatients undergoing intensive psychotherapy

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

7 January 2021

Fluoxetine for bulimia nervosa following poor response to psychotherapy

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

7 January 2021

Naloxone, an opiate blocker, reduces the consumption of sweet high-fat foods in obese and lean female binge eaters

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

7 January 2021

Pharmacological Treatment of Eating Disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

7 January 2021

Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

7 January 2021

Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

7 January 2021

Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

7 January 2021

Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

7 January 2021

Neuroleptics in the short-term treatment of anorexia nervosa. A double- blind placebo-controlled study with sulpiride

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

7 January 2021

Citalopram versus fluoxetine for the treatment of patients with bulimia nervosa: A single-blind randomized controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

7 January 2021

Altered Dopamine Activity after Recovery from Restricting-Type Anorexia Nervosa

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

7 January 2021

Serotonin neuronal function and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

7 January 2021

Low serotonin and dopamine metabolite concentrations in cerebrospinal fluid from bulimic patients with frequent binge episodes

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

7 January 2021

Does fluoxetine augment the inpatient treatment of anorexia nervosa?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

7 January 2021

Co-occurrence of binge eating disorder with psychiatric and medical disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

7 January 2021

A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

7 January 2021

Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

7 January 2021

Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

7 January 2021

Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145711000460

7 January 2021

10.1017/S1461145711000460

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21439105